⌕
United Therapeutics · UTHR · Nasdaq
Tenet 72 · Solid
Compare
$584.10−0.64%At closeTenet 72 · Solid
$584.10−3.78 (−0.64%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

United Therapeutics (UTHR) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice
Business engineGrowing fast: revenue compounds ~17.2%/yr (FY21→FY25), net margin 41.9%; free cash flow runs at 78% of net income. Check the accrual gap. Worth your attention in FY25: Capex step-up ($520.5M). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲10.6%
3,182.7
FY21→FY25CAGR +17.2%/yr
Net income ($M)▲11.7%
1,334.7
FY21→FY25CAGR +29.4%/yr
Free cash flow ($M)▼3.7%
1,040.7
capex stepped upCAGR +21.5%/yr
Diluted EPS▲13.1%
27.86
FY21→FY25CAGR +29.0%/yr
What the receipts whisper · what a headline number hides
Share count
+1.3%

47.3mn → 47.9mn diluted shares since FY21. Broadly flat, so EPS moves with net income rather than with the share count.

Capex step-up
$520.5M

▲111% YoY in FY25, largest jump in this window; watch free-cash-flow conversion.

Returns vs FCF
96%

$1.0B returned vs $1.0B of FCF in FY25. Buybacks covered by cash flow.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)3182.7Revenue−384.4COGS2798.3Gross profit−550.0R&D−755.8SG&A1492.5Op income−157.8Tax & other1334.7Net income

42¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.

Margin trend · direction beats level Gross Operating Net
1007550250%sector median net margin ~3%FY21FY25

Over this window: gross 92.7% → 87.9%. Net margin 41.9% is more than double the sector median.

The receipt · income statement · FY21–FY25 USD millions except per-share & ratios · hover a line for its definition
USD millions except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
3,187.53,182.72,877.42,327.51,936.31,685.5▲10.6%+17.2%
Cost of revenue
435.4384.4309.7257.5151.6122.5▲24.1%+33.1%
Gross profit
2,752.12,798.32,567.72,070.01,784.71,563.0▲9.0%+15.7%
Research & development
703.2550.0481.0408.0322.9540.1▲14.3%+0.5%
Selling, general & admin
727.8755.8709.7477.1482.1467.0▲6.5%+12.8%
Total operating expenses
1,431.01,305.81,190.7885.1805.01,007.1▲9.7%+6.7%
Operating incomefeeds ROC rank
1,321.11,492.51,377.01,184.9979.7555.9▲8.4%+28.0%
Other income, net
186.7221.4162.089.4−29.138.0——
Pretax income
1,507.81,713.91,539.01,274.3950.6593.9▲11.4%+30.3%
Income tax
277.0379.2343.9289.5223.3118.1▲10.3%+33.9%
Net incomePiotroski ROA ✓feeds Buffett Quality owner earnings
1,230.81,334.71,195.1984.8727.3475.8▲11.7%+29.4%
Per share
Diluted EPSbuyback-sensitive
26.4627.8624.6419.8115.0010.06▲13.1%+29.0%
Diluted shares (mn)
45.3047.9048.5049.7048.5047.30▼1.2%+0.3%
Margins
Gross margin81st pct in Healthcare
86.3%87.9%89.2%88.9%92.2%92.7%▼1.3pp−4.8pp
Operating margin
41.4%46.9%47.9%50.9%50.6%33.0%▼1.0pp+13.9pp
Net margin98th pct in Healthcare
38.6%41.9%41.5%42.3%37.6%28.2%▲0.4pp+13.7pp
† TTM = trailing four quarters through 2026-09-30.
FY08 – FY20 · 13 more years
Unlock the full history →
5 more years of statements and CSV export are on Premium, and 13 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-02-25 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was United Therapeutics' revenue last fiscal year?

United Therapeutics reported revenue of $3,182.7M in fiscal 2025, up 10.6% from fiscal 2024.

What was United Therapeutics' net income?

United Therapeutics reported net income of $1,334.7M in fiscal 2025, a net margin of 41.9%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.